April 12, 2017

BI and METACAM® (meloxicam) Declares 2017 the Year of the Small Dog

Company launches campaign to remind veterinarians and dog owners that small dogs can be affected by osteoarthritis, too

Duluth, GA – April 11, 2017 – Boehringer Ingelheim (BI), makers of METACAM® (meloxicam), today announced a year-long campaign to raise awareness that small-breed dogs are at risk for osteoarthritis (OA) as much as larger dogs. Throughout the year, veterinary practices will receive educational materials to help their teams learn more and to prompt conversations about OA in small dogs with their clients.

“Most older dogs will experience some degree of osteoarthritis,” said Dr. Arne Zislin, veterinary technical manager with BI. “However, small breeds can have different conditions that result in OA and can exhibit different symptoms than larger breeds.”

“When I was in private practice, I often had clients tell me their dogs were not as playful as they used to be, or their dog was slowing down,” Zislin added. “When I’d examine the dog, the diagnosis was often OA and not just old age. By prescribing the appropriate treatment and pain management protocol, clients often reported they were pleasantly surprised when their dogs returned to a more active lifestyle.”

Canine OA is often associated with larger breeds because of the well-known challenges bigger dogs often face with joint function and discomfort. However, small-breed dogs can also suffer from joint disease for a variety of reasons, including obesity, luxating patellas, trauma, Legg-Calve-Perthes disease, or normal wear and tear causing cartilage damage.

According to a November 2015 article in the American Kennel Club’s “Gazette,” an estimated 20 percent of dogs over 1 year of age have OA. “Because of the various medical conditions and lifestyles factors affecting them, smaller dogs have as much risk of OA as larger dogs,” Zislin added.

The Year of the Small Dog campaign will extend through 2017 and will include a website with OA-related information specifically for smaller dogs; awareness-raising ads in veterinary trade journals; outreach to trade and consumer journalists to encourage media coverage of the topic; and information veterinarians can provide to educate their clients about OA in smaller dogs.

“We hope that through this effort, OA is more commonly recognized and diagnosed in smaller dogs,” Zislin said. “And that those dogs can live happier, healthier lives.”

About METACAM

METACAM (meloxicam oral suspension) and METACAM (meloxicam) 5mg/mL Solution for Injection are indicated in dogs for the control of pain and inflammation associated with osteoarthritis.

Along with precise dosing, METACAM also offers:

  • Honey flavoring that mixes well with food
  • Convenient oral liquid administration
  • Also available as an injection for rapid pain relief
  • 20+ year track record
  • Every bottle of METACAM is backed by Boehringer Ingelheim, a company veterinarians know and trust

For more information about METACAM, please go to https://www.metacam.com.

MPORTANT SAFETY INFORMATION for METACAM (meloxicam oral suspension) and METACAM (meloxicam) Solution for Injection: METACAM (meloxicam oral suspension) is for use in dogs only. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, kidney, or liver side effects. The most common side effects reported in field studies were vomiting and soft stool/diarrhea. These are usually mild, but may be serious. If side effects occur, dog owners should halt therapy and contact their veterinarian. Dogs should be evaluated for pre-existing conditions and currently prescribed medications prior to treatment with METACAM, then monitored regularly while on therapy. Concurrent use with another NSAID, corticosteroid, or nephrotoxic medication should be avoided or monitored closely. The safe use of METACAM in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating bitches has not been evaluated. Please refer to the package insert for complete product information or visit www.metacam.com.

About Boehringer Ingelheim Animal Health

In January 2017, Merial became part of the Boehringer Ingelheim group. As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.